Digital Health / Virtual Care / Chronic Disease Management
Strategic Profile
Omada significantly outpaces competitors in monthly global app downloads with downloads approaching 80,000 by January 2026 compared to most competitors hovering around or below 20,000. The company differentiates its offering through multi-condition care, evidence with 30 peer-reviewed publications and four accreditations, compassionate intelligence combining care teams with technology, and scaled diversified go-to-market serving over 2,000 customers. In May 2026, Omada announced it will serve as an independent program administrator in Eli Lilly and Company's Employer Connect program, with GLP-1 Care Track available on the direct-to-employer platform.
Cyborg Score Rationale
Omada achieved $78 million in Q1 2026 revenue, up 42% year over year, with positive adjusted EBITDA and margin expansion. The company achieved its first positive quarterly adjusted EBITDA in Q3 2025 at $2.4 million, followed by $8.5 million in Q4 2025. However, two partners affiliated with The Cigna Group each provided 33% of Q1 2026 revenue and together accounted for 64% of accounts receivable, creating meaningful customer concentration risk.
Top Insights
In May 2026, Omada joined Optum Rx's Weight Engage portfolio to help employers expand clinically supported access to GLP-1 and other anti-obesity medications through pharmacy benefit managers.
Omada raised its full-year 2026 revenue guidance to $322 million to $330 million in May 2026, up from the previous range of $312 million to $322 million.
A new clinical analysis showed that Omada members in the GLP-1 Care Track lost on average 1.8 times the total weight and more than two times the percentage of body fat compared to a control group over a 12-week period.
Management is investing in AI-powered tools including OmadaSpark and MealMap to enhance member engagement, with plans for full rollout of a standalone Cholesterol program in 2027.
Named Competitors
Hinge Health — Digital musculoskeletal care platform
Virta — Type 2 diabetes reversal program
Livongo — Chronic disease management platform
GLP-1 Management Services — Integrated pharmacy and medication management
Recent Developments
(May 2026) Raised full-year 2026 revenue guidance to $322-$330 million and announced partnership with Eli Lilly's Employer Connect program as independent program administrator
(May 2026) Reported Q1 2026 revenue of $78 million with 42% YoY growth, surpassed one million total members, and achieved positive adjusted EBITDA
(April 2026) Published clinical study results showing GLP-1 Care Track members lost 1.8x more total weight versus control group
(June 2025) IPO on NASDAQ at $19 per share, raised $150 million
Open the full interactive Omada Health, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.